Found 699 none trials
A listing of none medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
C
Chace Brokaw Chace Brokaw
Please see section 3 of the full protocol Please see section 3 of the full protocol Please see section 3 of the full protocol PI123
E
EDWARD STADTMAUER
See protocol section 2 See protocol section 2 See protocol section 2
The main goal of this study is to utilize previously validated cytometric markers of to identify cancer patients at high risk of VTE. The primary outcome will be DVT or pulmonary embolism (PE). Patients with pancreatic and brain cancer will be enrolled as these patients are known to have higher …
Traumatic cerebrovascular injury (TCVI) is common after traumatic brain injury (TBI) and an attractive target for therapeutic intervention. We will longitudinally measure cerebrovascular reactivity (CVR) by functional near-infrared spectroscopy (fNIRS) in acute (3 days from injury), subacute, and chronic phases after TBI as a biomarker of TCVI as compared to …
Since its launch in 2004, the overarching aim of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI1, ADNI-GO, and ADNI2 studies that have been combined public/private collaborations between academia and industry to determine the …
WAIHA is caused by antibodies (proteins) that attach to red blood cells and causes their destruction. This causes anemia, which means the red blood cell count in the body becomes low. This medical research study is being done to find out more information about the investigational drug SYNT001 for the …
Traumatic brain injury (TBI) is among the leading causes of death and disability worldwide with enormous social and economic impacts. The heterogeneity of TBI, combined with the lack of precise outcome measures, have been central to the discouraging results from numerous clinical trials. Current approaches to the characterization of disease …
The main purpose of this study is to find the best dose of hydroxychloroquine (HCQ) when given in combination with regorafenib and entinostat.
Cognition Therapeutics is developing an oral formulation of CT1812 to treat AD and mild cognitive impairment. This is a multi-center, Phase 1b, randomized, double-blind, placebo-controlled parallel-group trial in adults with mild to moderate AD, sponsored by the NIH. The primary purpose of this study is to evaluate target engagement of …
